文献速递药物不良反应与药物警戒

通过个例安全性报告的不比例分析识别劣质药品

Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
PubMed 文献 · Drug Saf · 2017-01-01

该研究基于WHO VigiBase数据库2001至2014年的个例安全性报告,采用MGPS算法和24个MedDRA首选术语进行三种分层分析,以EB05≥2.0为阈值筛选出2506个命中信号,经进一步调查和五个药品的试点研究得出23个潜在劣质药品,文献检索验证了利斯的明贴剂等发现。

要点

  • 自发报告数据挖掘可用于识别潜在劣质药品,EB05≥2.0为筛选阈值。
  • 分层分析结合24个产品问题相关首选术语可提高信号检出。
  • 文献验证支持该方法可复现UMC此前确认的劣质药品信号。

核心结论

  • 自发不良事件报告的数据挖掘和不比例分析可用于识别潜在劣质药品。

研究设计与样本

  • 采用MGPS算法通过Oracle Empirica软件进行三种分层分析,使用24个MedDRA首选术语识别劣质药品。
  • 以EB05(EBGM的95%置信区间下限)≥2.0为阈值筛选潜在劣质药品。
  • 对五个上市许可持有人授权的药品(缬沙坦、哌甲酯、利斯的明、氯氮平、卡马西平)进行进一步调查和试点研究。
  • 通过文献检索相关警示信验证发现,并评估能否确认UMC首次识别的两个劣质药品。

主要发现

  • 按选定标准和阈值分析个例安全性报告,得到2506个命中,包括产品品质缺陷报告相对过多的药品。
  • 进一步调查和五个药品的试点研究得出23个潜在劣质药品。
  • 文献检索发现两份关于劣质利斯的明贴剂的卫生专业人员通讯,验证了初步发现。
  • 发现炔雌醇/诺孕酯复方和沙丁胺醇的产品质量问题报告过多,UMC于2014年将其归类为确认的SSFFC医疗产品集群。

关键数值与推荐

  • 使用24个MedDRA首选术语识别劣质药品。
  • EB05阈值设为2.0用于筛选潜在劣质药品。
  • 分析产生2506个命中,进一步调查后输出23个潜在劣质药品。

临床怎么用

  • 临床药学可关注自发报告中产品品质问题相关术语的聚集信号。
  • 对EB05≥2.0的药品信号可结合文献和监管通讯进一步评估。
  • 该方法可作为传统大规模检测技术外的补充筛查手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The distribution and use of substandard medicines (SSMs) is a public health concern worldwide. The detection of SSMs is currently limited to expensive large-scale assay techniques such as high-performance liquid chromatography (HPLC). Since 2013, the Pharmacovigilance Department at Novartis Pharma AG has been analyzing drug-associated adverse events related to 'product quality issues' with the aim of detecting defective medicines using spontaneous reporting. The method of identifying SSMs with spontaneous reporting was pioneered by the Monitoring Medicines project in 2011. METHODS: This retrospective review was based on data from the World Health Organization (WHO) Global individual case safety report (ICSR) database VigiBase® collected from January 2001 to December 2014. We conducted three different stratification analyses using the Multi-item Gamma Poisson Shrinker (MGPS) algorithm through the Oracle Empirica data-mining software. In total, 24 preferred terms (PTs) from the Medical Dictionary for Regulatory Activities (MedDRA®) were used to identify poor-quality medicines. To identify potential SSMs for further evaluation, a cutoff of 2.0 for EB05, the lower 95% interval of the empirical Bayes geometric mean (EBGM) was applied. We carried out a literature search for advisory letters related to defective medicinal products to validate our findings. Furthermore, we aimed to assess whether we could confirm two SSMs first identified by the Uppsala Monitoring Centre (UMC) with our stratification method. RESULTS: The analysis of ICSRs based on the specified selection criteria and threshold yielded 2506 hits including medicinal products with an excess of reports of product quality defects relative to other medicines in the database. Further investigations and a pilot study in five authorized medicinal products (proprietary and generic) licensed by a single marketing authorization holder, containing valsartan, methylphenidate, rivastigmine, clozapine, or carbamazepine, were performed. This resulted in an output of 23 potential SSMs. The literature search identified two communications issued to health professionals concerning a substandard rivastigmine patch, which validated our initial findings. Furthermore, we identified excess reporting of product quality issues with an ethinyl estradiol/norgestrel combination and with salbutamol. These were categorized as confirmed clusters of substandard/spurious/falsely labelled/falsified/counterfeit (SSFFC) medical products by the UMC in 2014. CONCLUSION: This study illustrates the value of data mining of spontaneous adverse event reports and the applicability of disproportionality analysis to identify potential SSMs.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Trippe ZA, Brendani B, Meier C, et al. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports. Drug Saf. 2017. PMID: 28130773. doi:10.1007/s40264-016-0499-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。